These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12884153)

  • 1. [Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
    Traut V
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1618; author reply 1618. PubMed ID: 12884153
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute vs. relative numbers in evaluating drug therapy.
    McCormack J
    Am Fam Physician; 2001 May; 63(10):1913-4, 1916. PubMed ID: 11388707
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
    Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
    Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
    Kruse HP
    MMW Fortschr Med; 2001 Nov; 143(47):33-6. PubMed ID: 11791359
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteoporosis in men.
    Cefalu CA
    Am Fam Physician; 2001 Jun; 63(12):2331-2. PubMed ID: 11430449
    [No Abstract]   [Full Text] [Related]  

  • 7. [Osteoporosis treatment: choices and options].
    Reginster JY
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract]   [Full Text] [Related]  

  • 8. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 9. Paget's disease and bisphosphonates.
    Liel Y
    N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16354901
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
    Bannwarth B
    Presse Med; 2002 Mar; 31(8):340-2. PubMed ID: 11913075
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
    MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
    [No Abstract]   [Full Text] [Related]  

  • 14. [New guideline for the treatment of osteoporosis].
    Matsumoto T
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():387-91. PubMed ID: 15035157
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the increase in osteoporosis prevention a result of the audit?
    Naunton M
    Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
    [No Abstract]   [Full Text] [Related]  

  • 16. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
    Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
    J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate (Fosamax) and risedronate (Actonel) revisited.
    Obstet Gynecol; 2005 Aug; 106(2):402-4. PubMed ID: 16055597
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
    Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.